04/15/2026
Autoantibodies involvement in neuropsychiatric decline.
Wlhen children experience a sudden and severe decline in behavior, mood, or movement—often following an infection or major physical stress—it can be deeply distressing for families and challenging for clinicians. This kind of acute neuropsychiatric change is sometimes seen in children with autism or other neurodevelopmental conditions, but it can also occur in children who previously showed no developmental concerns.
Research points to brain inflammation and the immune system as a possible contributor in some cases. Research from the laboratory of Samuel Pleasure, MD, PhD, at UCSF, has identified a novel autoantibody that targets the CD320 protein, which is essential for transporting vitamin B12 into the brain. When this mechanism is disrupted, the brain can become functionally deficient in B12, potentially leading to neurological and psychiatric symptoms ranging from motor and sensory difficulties to significant behavioral changes.
Early evidence suggests that these anti-CD320 autoantibodies may be surprisingly common—particularly among children with autism. Mouse studies further indicate that blocking CD320 triggers cellular stress responses in the brain, offering a new window into understanding how inflammation and metabolism intersect in neuropsychiatric disease.
The newly-awarded grant by the The BRAIN Foundation will now support researchers in taking this discovery to the next level. Together with co-investigators Michael Wilson, MD (UCSF) and Jennifer Frankovich, MD, MS (Stanford), the team will employ cutting-edge screening technologies and an unbiased phage-display platform to analyze large groups of children and identify both anti-CD320 and other novel neural autoantibodies linked to acute neuropsychiatric decline.
This initiative represents a major step forward in uncovering the biological causes of sudden behavioral and cognitive changes in children. By pinpointing these underlying mechanisms, researchers hope to pave the way toward earlier diagnosis, improved understanding of disease subtypes, and ultimately, more targeted treatments for affected children and familiesWhen children experience a sudden and severe decline in behavior, mood, or movement—often following an infection or major physical stress—it can be deeply distressing for families and challenging for clinicians. This kind of acute neuropsychiatric change is sometimes seen in children with autism or other neurodevelopmental conditions, but it can also occur in children who previously showed no developmental concerns.
Research points to brain inflammation and the immune system as a possible contributor in some cases. Research from the laboratory of Samuel Pleasure, MD, PhD, at UCSF, has identified a novel autoantibody that targets the CD320 protein, which is essential for transporting vitamin B12 into the brain. When this mechanism is disrupted, the brain can become functionally deficient in B12, potentially leading to neurological and psychiatric symptoms ranging from motor and sensory difficulties to significant behavioral changes.
Early evidence suggests that these anti-CD320 autoantibodies may be surprisingly common—particularly among children with autism. Mouse studies further indicate that blocking CD320 triggers cellular stress responses in the brain, offering a new window into understanding how inflammation and metabolism intersect in neuropsychiatric disease.
The newly-awarded grant by the The BRAIN Foundation will now support researchers in taking this discovery to the next level. Together with co-investigators Michael Wilson, MD (UCSF) and Jennifer Frankovich, MD, MS (Stanford), the team will employ cutting-edge screening technologies and an unbiased phage-display platform to analyze large groups of children and identify both anti-CD320 and other novel neural autoantibodies linked to acute neuropsychiatric decline.
This initiative represents a major step forward in uncovering the biological causes of sudden behavioral and cognitive changes in children. By pinpointing these underlying mechanisms, researchers hope to pave the way toward earlier diagnosis, improved understanding of disease subtypes, and ultimately, more targeted treatments for affected children and families
